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ABSTRACT 
 
Background : Transcranial direct current stimulation (tDCS) is a potential alternative treatment option for major 
depressive episodes (MDE). Objectives: We address the efficacy and safety of tDCS in MDE. Methods:  The 
outcome measures were Hedges‟ g for continuous depression ratings, and categorical response and remission 
rates. Results: A random effects model indicated that tDCS was superior to sham tDCS (k=11, N = 393, g=0.30, 
95% CI=[0.04, 0.57], p= .027). Adjunctive antidepressant medication and cognitive control training, negatively 
impacted on the treatment effect. The pooled log odds ratios (LOR) for response and remission were positive, but 
statistically non-significant (response: k= 9, LOR = 0.36, 95% CI[-0.16, 0.88], p = .176,  remission: k= 9, LOR = 
0.25, 95% CI [-0.42, 0.91], p = .468). We estimated that for a study to detect the pooled continuous effect  
(g=0.30) at 80% power (alpha = .05), a total N of at least 346 would be required (with the total N required to 
detect the upper and lower bound being 49 and 12693 respectively). 
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 Conclusions:  tDCS may be efficacious for treatment of MDE. The data do not support the use of tDCS in 
treatment-resistant depression, or as an add-on augmentation treatment . Larger studies over longer treatment 
periods are needed. 
 
Key words:  Depression, meta-analysis, non-pharmacological therapies, systematic review, transcranial direct 
current stimulation, tDCS, Response, Remission, Cognitive Control Training.  
  
1. BACKGROUND 
 
Depressive disorders are prevalent, recurrent, often run a chronic course, and are associated with significant 
worldwide morbidity and mortality2,3. Treatment with antidepressant medication is often suboptimal in terms of 
efficacy, safety and tolerability4,5. Psychological interventions are associated with significant rates of suboptimal 
effectiveness, even when combined with antidepressant medication6. Electro-Convulsive Therapy (ECT) is highly 
effective, but is associated with significant stigma, and adverse effects6. Other invasive and non-invasive 
neurostimulation modalities have been proposed for the treatment of depression, but their utility may be limited 
by issues such as cost, tolerability and availability7. In particular, there are important differences between tDCS and 
repetitive transcranial magnetic stimulation (rTMS) in terms of adverse effect profiles, focality of stimulation, and 
also in the cost, availability and portability of equipment7. Trans-cranial direct current stimulation (tDCS) is a novel 
treatment modality for depression, which may represent an alternative to pharmacological or psychological 
treatments. tDCS is a non-invasive brain stimulation modality, which changes cortical tissue „excitability‟ as a 
result of applying a weak (0.5-2mA) direct current via scalp electrodes overlying targeted cortical areas. In 
contrast to other neurostimulation modalities, tDCS does not directly trigger action potentials in neuronal cells, 
but instead changes overall tissue excitability, and therefore may be more aptly regarded as a „neuro-modulatory‟ 
rather than a neuro-stimulatory approach 7. Cortical tissue underlying the anode (positive electrode) becomes 
hypo-polarized, and therefore hyper-excitable; areas underlying the cathode (negative electrode) become less 
excitable as the average resting potential becomes more polarized. The magnitude of these membrane 
polarization changes is not in itself sufficient to directly cause neurons to fire 8. These effects continue after 
electrical stimulation ceases, and a single application can be associated with tissue excitability changes lasting 
more than 60 minutes 9,10. These findings suggest tDCS is likely to be associated not only with transient membrane 
polarization changes, but also with longer-lasting synaptic changes 11.  
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The body of research describing the efficacy, safety and tolerability of tDCS in depression is growing. Three earlier 
meta-analyses have been published 12-14, these used different methodologies and produced inconsistent findings. 
We therefore performed a systematic review and meta-analysis of the efficacy and tolerability of tDCS in 
depression, using a comprehensive set of meta-analytic tools, and incorporating all published randomised 
controlled trials to date. 
 
2. METHOD 
A literature search and meta analysis were conducted following the recommendations of the Cochrane 
collaboration15 and the PRISMA guidelines1. Two authors (DM and NH) performed the systematic review and data 
extraction. All discrepancies were resolved by consensus. 
 
2.1 LITERATURE REVIEW 
We searched the PubMed database using the following search strategy: 
((((((“direct”[Title/Abstract]) AND “stimulation”[Title/Abstract])) OR “tdcs”[Title/Abstract])) AND 
((“rand*”[Title/Abstract]) OR “control*”)) AND “depress*”[Title/Abstract]. The date range extended up to April 30th, 
2015. We also scrutinized the reference lists in published meta-analyses of tDCS in depression and articles listed 
as citing these meta-analyses12-14. 
Inclusion criteria used were: English language publications; Randomised, sham-controlled trials. Including data 
enabling calculation of effect size for depression rating scale change, and/or response/remission rates. Patient 
population with depressive disorders. tDCS as monotherapy or augmentation therapy for treatment of depression. 
Exclusion criteria used were: Studies in animals. Non-controlled or non-randomised trials. Case reports / case 
series. Trials of treatments for disorders other than depression. Trials of interventions other than tDCS. Duplicated 
data-sets. 
 
2.2 DATA EXTRACTION  
The following data were extracted: Population demographics including sample size. Diagnosis (unipolar/bipolar 
depression). tDCS characteristics (including number of sessions, montage, current used, inter-session intervals, 
sham stimulation characteristics). Efficacy outcome measures and outcomes  (Including rating scale score changes 
and response/remission rates). Acceptability (using dropout numbers as a proxy measure). 
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Outcome measures included both continuous depression rating scale scores, and categorical response/remission 
rates - we included both types of outcome for the following reasons: First, previous meta-analyses utilised 
continuous outcome measures 12, categorical outcome measures 13, or both 14, which may explain the inconclusive 
and at times contradictory nature of their findings. Second, whereas continuous outcome measures may offer 
superior sensitivity, their specificity is considered inferior to that of categorical outcome measures. Third, while 
categorical response/remission rates may be more clinically „meaningful‟, they require larger sample sizes, and as 
all studies included in our meta-analysis utilised continuous primary outcome measures, they may have lacked 
sufficient statistical power to reliably test hypotheses based on categorical outcomes. 
 
We therefore extracted the following data: for continuous outcomes we meta-analysed depression rating scale 
scores at randomised blinded treatment endpoint, using the study primary outcome measure rating scale; for 
categorical outcomes, we meta-analysed remission and response rates for active and sham groups at randomised 
blinded treatment endpoint. Response was defined as ≥ 50% reduction in depression rating scale score from 
baseline to endpoint; we used the specified remission criteria provided by each study. 
 
2.3 META ANALYSIS 
Our adopted meta-analytic approach makes several important contributions to the literature (Table 2). We: 
1. increase the number of included RCTs and subjects, compared to previous meta-analyses. 
2. use a methodology combining continuous outcome measures (rating scale scores) with possibly more 
clinically relevant dichotomous measures (i.e. response and remission rates). 
3. perform moderator analyses to clarify the effect of putative moderators identified in narrative analysis. 
4. perform power and precision analyses to inform future research in terms of sample size planning. 
5. identify important gaps in knowledge and suggest new directions for future research, methodological 
improvements and improved reporting standards.  
6. Examine the use of tDCS in conjunction with antidepressant medication and with Cognitive Control 
Training (CCT) 
7. clarify in which conditions tDCS might be clinically useful.  
 
The primary effect size index used to quantify the continuous treatment effect was Hedge‟s g - the difference in 
the reduction in depression severity rating scale scores (MADRS and/or HDRS) between the two groups (active 
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tDCS – sham tDCS). This was calculated by subtracting the Hedge‟s g for the difference in depression ratings 
between groups before treatment from the corresponding difference immediately after treatment. A positive value 
of g represents a larger decrease in depression severity rating in the treatment group, relative to the control 
group.  Our choice of standardizer for g was the pooled within-groups SD (SDpooled), as this has more degrees of 
freedom (since it is derived from two groups) than other standardisers and is thus likely to be the most precise 
estimate of the population SD. We chose the “bias corrected” Hedges g since it provides superior point estimates 
over Cohen‟s d which inflates point estimates for small samples. However, following best practice, our confidence 
intervals were uncorrected, since simulations show that confidence intervals on d provide more accurate interval 
estimates16. For each study, we computed g and 95% confidence intervals by using a combination of means, 
standard deviations, independent samples t, p and F statistics using the R programming language. In practice, 
these were the same routines implemented by the widely used Comprehensive Meta Analysis Software (CMA: 
Biostat, Englewood, NJ). 
 
We performed two additional meta-analyses to quantify the overall treatment effect in terms of categorical 
response and remission rates4. In both cases, we compared the differences between treatment and control groups 
by using the log odds ratio as an effect size index. A positive score represents a higher likelihood of response or 
remission in the treatment (active tDCS) group, relative to the control (sham tDCS) group. Response was defined as 
50% reduction in depression rating scale score from baseline to endpoint.  We used the remission criteria provided 
by each study. 
 
As previous meta-analyses have indicated considerable heterogeneity in effect size estimates between studies 12, 
we made an a priori decision to analyse our effect size data using a random effects model, due to its tolerance of 
heterogeneous effect sizes and conservative nature of estimation 16,17. The random effects model assumes that 
each study estimates different values from a distribution of population parameters, rather than assuming studies 
are direct replications of each other.  We assessed heterogeneity across effect sizes by using Cochran's Q and I2 
statistics. Unless reported otherwise, parameter estimates were obtained via restricted maximum likelihood 
estimation, due to its accuracy relative to other estimators with smaller numbers of studies18. Statistical tests of 
model coefficients were computed via Wald-type chi squared tests. We additionally used a pseudo-R2 statistic to 
assess the amount of heterogeneity between effects explained by including moderators 19.  R2 estimates the 
proportional reduction in heterogeneity after including moderators. For interpretation, it is important to note that 
this pseudo-R2 does not include sampling variability, meaning that it is possible to get very large R2 values, even 
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when there are discrepancies between the model and the observed effects (provided these are not larger than 
expected by sampling variability). Model comparisons were conducted via likelihood ratio tests. All meta analyses 
were performed using the "metafor" package in R20. 
 
To account for heterogeneity across treatment effects, we assessed the impact of potential categorical and 
continuous moderators of the treatment effect. The moderators we examined are listed in table 1. Moderator data 
for each study were recorded in a structured fashion. Where the information was reported, we recorded both 
categorical moderators and continuous moderators. Two experienced authors (NH, DM) acted together as coders, 
and no disagreements on coding decisions were encountered.  
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Potential moderator Units Descriptive Statistics 
Current  mA (Boolean) k = 11 
1mA (k = 2) 
2mA (k = 9) 
Course delivered Number of sessions  k= 11 
M= 9.55 
SD = 3.50 
Range = 5-15 
Session duration Minutes per session (Boolean) 
k = 11 
20 mins (k=7) 
30 mins (k=4) 
Total tDCS time Number of sessions x session 
duration (minutes) 
k= 11 
M =229.09 
SD = 87.80 
Range = 100- 300 
Total current delivered mA x number of sessions x session 
duration 
k = 11 
M = 430.91 
SD = 210.97 
Range = 100- 600 
Inter-session intervals Days (Boolean) k = 11 
1 day (k=9) 
2 days (k=2) 
Diagnosis  k=11 
unipolar (k=9) 
unipolar and bipolar (k=2) 
Concurrent anti-depressant 
medications (ADMs) 
 k=11 
Concurrent ADMs (k=8) 
No-concurrent ADMs (k=3) 
Concurrent cognitive control 
therapy (CCT) 
 k=11 
Concurrent CCT (k=2) 
No concurrent CCT (k=9) 
   
Treatment resistance level Number of previous courses of 
antidepressants failed in current 
episode 
k= 9 (see table 3) 
 
   
   
 
Table 1: variables examined as potential moderators of tDCS outcomes in depression. These include both 
participant-related and tDCS-related factors, with a view to enable meta-analytical examination of the variables 
found to be associated with tDCS outcomes in the narrative analysis.  
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Additional analyses: publication bias, precision and power 
To assess the impact of the so-called "file drawer problem", whereby unpublished null results can distort meta-
analytic estimates, we performed „fail-safe N‟ analyses using the methods developed by Orwin  21 and Rosenthal 22. 
This allowed estimation of the total number of unpublished studies averaging null effects that would be required 
to reduce the reported treatment effect size to target levels 21 or to statistical non-significance 22. Despite the 
existence of other meta-analyses estimating the magnitude of tDCS efficacy, to date there has been no formal, 
explicit attempt to use these parameter estimates to inform future research planning. We hence addressed this 
issue from both an Accuracy In Parameter Estimation (AIPE), and power analytic perspective. The AIPE analyses 
were used to estimate the appropriate sample size for future trials such that the expected width of the confidence 
interval meets a desired level of precision 16. Unlike power analysis, this approach negates the need to invoke a null 
hypothesis significance test, and instead is solely concerned with precision in parameter estimation.  This was 
achieved by using the non-central t method described by Kelley23, implemented in the "MBESS" package in R 24. To 
provide an assessment of the statistical power of individual studies, we estimated the power of each study to 
detect the summary effect estimated in the meta-analysis at a nominal level of significance (p=.05). By extension, 
for future sample size planning, we calculated the minimum N required to achieve adequate (80%) power to detect 
the estimated summary effect.  
 
3. RESULTS: EFFICACY 
3.1 Randomized Controlled Trials (RCTs): We identified ten randomized controlled trials of tDCS in depression 
using PRISMA methodology (Figure 1a), and quality-assessed the each trial using the Cochrane Collaboration‟s tool 
for assessing risk of bias in randomised trials25 – this yielded an acceptable profile of Risk of Bias across the RCTs 
included in the meta-analysis (Figure 1b). Due to the diversity of study designs, we made the following decisions 
about the analysis of individual studies: 1. Boggio et al. (2008) 26 randomised participants to 3 groups: active tDCS 
over left DLPFC, sham tDCS over left DLPFC, and active occipital tDCS; we chose to exclude the occipital group 
from our meta-analysis. 2. In analyzing the Brunoni et al. 2013 trial27 , we separated the data from participants 
who received sertraline and those who received placebo medication - this created two separate effects (hence 
although we included 10 RCTs, we analyzed k=11 effects).3. Segrave et al (2014)28 randomised participants to 3 
groups: 1.tDCS + Cognitive Control Training (CCT), or 2.sham tDCS + CCT, or 3. tDCS + sham CCT - For the 
purpose of this meta-analysis, we included only 2 of the 3 study arms – comparing tDCS+CCT vs. sham 
tDCS+CCT. 4. Several studies reported primary outcomes at endpoints which included a follow-up period after the 
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end of active treatment course. For the sake of consistency, we analysed all available data at the point when active 
blinded treatment ceased.  
 
3.1.1 Fregni 2006
29. 
Study. A randomised double blind sham controlled trial in which 18 outpatients with (unipolar) MDD who had not 
been prescribed antidepressant medication for at least three months prior to inclusion were randomised to 2 
treatment arms: either active tDCS, in which the anodal electrode was placed over F3 (10-20 International EEG 
System), and the cathode over the right supra-orbital area, a current of 1mA being applied for 20 minutes on 5 
alternate days; or sham tDCS with similar settings, but the stimulator being switched off after 5 seconds. Outcome 
measures involved a battery of neuropsychological rating scales; mood was assessed with the HDRS. The active 
treatment group showed a significantly greater improvement in mood, mean Hamilton Depression Rating Scale 
(HDRS) scores reduced by 58.5% (+/-20.4%) vs. 13.1% (+/-23.4%) in the sham tDCS group [F(1,16)=19.2, 
p<0.001]. tDCS was generally well tolerated, and no complications were reported. The active tDCS group improved 
on all cognitive tests, compared to their baseline scores. There was no significant cognitive improvement in the 
sham tDCS group. Improvement in cognitive function in the treatment group was not correlated with the 
improvement in mood, suggesting that cognitive and affective changes were mediated by different mechanisms. 
 
Comment. Although involving a small number of participants, this study found evidence for antidepressant 
efficacy and tolerability of tDCS in MDD. The sample baseline characteristics were well defined, with moderate-to-
marked baseline depressive severity (mean HDRS scores of 23.56+/-5.03 in the active tDCS group and 25.89+/-
4.26 in the sham group), significant number of patients had recurrent or persistent illness. 
 
3.1.2 Boggio 2008 
26. 
Study. Following this pilot study, the same group conducted a parallel-group, double-blind, initial clinical trial of 
tDCS in patients with unipolar depression who had not been prescribed antidepressants for at least two months 
prior to trial entry. Exclusion criteria included neurological disorders, comorbid Axis I disorders, substance abuse 
within three months of study participation, psychotic features, bipolar disorder and Axis II disorders. Forty 
patients were randomized into three treatment arms (using a 2:1:1 randomization strategy): active treatment, with 
anodal tDCS over the left dorsolateral prefrontal cortex (DLPFC) - anode over F3 on the 10-20 International EEG 
System, cathode over right supraorbital region  (N=21); active control, with anodal tDCS of the occipital cortex - 
anode 2cm above Inion on the midline, cathode over right supraorbital region (N=9); or sham control with sham 
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tDCS over left DLPFC, and cathode over the right supraorbital region, the stimulator being active for an initial 30 
seconds only, with ramp-up and ramp-down to mask shamming (N=10). Patients received 10 sessions of tDCS on 
consecutive working days (no treatment being given at weekends), the current was set at 2mA for 20 minutes in 
each session. The primary outcome measure was the 21-item HDRS, the BDI being the secondary outcome 
measure. Patients were rated at baseline, at end of treatment and at 15 and 30 days after treatment. tDCS was well 
tolerated, reported adverse effects being mild (headache, itching or redness at electrode site) and not significantly 
associated with group assignment. At the end of treatment, there was a significant difference between the active 
treatment group and the active control group (p=0.009) and the sham control group (p=0.0018) in HDRS score; 
but the control groups did not separate from each other (p=0.6). The active group maintained separation from the 
sham control at the 30-day follow-up (p=0.04). BDI outcomes showed a similar pattern, with the active group 
separating from the sham group at the end of treatment (p=0.0045, effect size (Cohen's d) =1.11), and at 30-day 
follow-up (p=0.03). There were 8 responders (HDRS scores reduced by at least 50% from baseline) in the active 
treatment group, compared with 2 in the active control and none in the sham control groups (p=0.019). There 
were 5 patients in remission (HDRS < 8) in the active treatment group, but none in the other two groups (p=0.02).  
 
Comment. This study was larger than previous studies of tDCS in depression and demonstrated both acute efficacy 
and an effect lasting 30 days after treatment was stopped. The findings provide support for the use of left DLPFC 
anodal stimulation. This was the first study to indicate that the therapeutic effect in depression is related to the 
anodal effect at left DLPFC rather than to the cathodal effect at the right supra-orbital area. The tolerability of 
active tDCS was not significantly different to sham stimulation. 
 
3.1.3 Loo (2010) 
30   
This double-blind, sham-controlled trial of left prefrontal tDCS in depression involved 40 outpatients with DSM-IV 
MDD with baseline MADRS (Montgomery-Åsberg Depression Rating Scale) score of 20 or more. Exclusion criteria 
included diagnosis of bipolar disorder, drug or alcohol dependence or abuse, other Axis-I disorders, and 
neurological disorders; or the failure to respond to ECT during the index episode. Subjects were either 
medication-free, or had continued on the antidepressant drug to which they had not previously responded at a 
stable dose, unaltered for at least 4 weeks prior to study enrolment (some patients were prescribed antipsychotic 
drugs, and 1 patient was prescribed lamotrigine: none were prescribed benzodiazepines). Subjects were 
randomised to: [i] active tDCS with anodal tDCS over left DLPFC (pF3 on the10/20 EEG International System), the 
cathode being placed over the right lateral orbital area: 1 mA of current was used for 20 minutes, with 30 seconds 
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of ramping-up at onset; [ii] sham tDCS with a similar montage, the current being ramped down over 30 seconds 
immediately after initial ramping up. Subjects in both arms underwent treatment three times weekly for five 
treatment sessions. All subjects then received active tDCS for another five sessions (at the same frequency). After 
10 sessions, the blind was broken and patients who had received sham tDCS in sessions 1-5 were then offered 
another 5 sessions of active tDCS - bringing the total number of active tDCS sessions offered to all participants 
(regardless of treatment arm assignation) to 10. The primary mood outcome measure was the MADRS, and 
secondary outcome measures included the 17-item HDRS and Clinical Global Impression of Severity (CGI-S), the 
patient-rated BDI and Patient Global Impression Scale of Improvement (PGI-I). Subjects were assessed at baseline, 
after sessions 5, 10 and 15, and at 1-week and 1-month follow-up. Over the sham-controlled phase (sessions 1-
5) there were no significant between-group differences in mood outcomes (p=0.87 for MADRS). There were 
statistically significant differences on all measures comparing baseline mood to mood after session 10, but no 
significant differences between groups. There were 6 responders (MADRS score reductions of at least 50%) and 5 
remitters (MADRS<11) in the active tDCS group, compared to 4 responders and 3 remitters in the sham group. 
One patient in the sham tDCS group committed suicide on the day following his first active tDCS session: the 
authors felt this was unlikely to have been related to the treatment this patient received (the patient had been 
noted to have suicidal thoughts for some months prior to his death, the suicide occurred on the first instance 
when he was briefly left on his own, and there were no emotional or clinical changes noted following the session 
of active tDCS that he had received). Adverse effects reported by the active tDCS group included redness, itchiness 
and tingling at electrode (mainly anode) sites; mild headaches, lightheadedness and ringing in the ears; visual 
changes including blurring, brighter/illuminated vision; and mild euphoria, transient hypomania (N=1), nausea, 
insomnia and anxiety. After session 10, subjects were asked to indicate whether they thought they had received 
active or sham tDCS, there being no significant in the accuracy of identification between the two groups. 
 
Comment. This study used similar stimulation parameters to those used by Fregni et al 200629,31 (five 20 minute 
sessions at 1mA on alternate days with similar electrode montage,) but did not show a statistically significant 
separation between active and sham tDCS groups. The efficacy of active treatment over 10 sessions was 
comparable to that demonstrated by Boggio et al.26 who used tDCS at higher intensity (2mA, 5 times weekly for 10 
sessions). The main difference between this study and the earlier trials was the greater degree of improvement in 
the sham tDCS group. Factors which may have contributed to this difference included the participation of patients 
taking antidepressants and patients with co-morbid Axis II (personality) disorders. The degree of treatment 
resistance in this cohort was only „moderate‟ (mainly stage 0-III on the Thase & Rush system 32, which may explain 
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the magnitude of sham tDCS effects in this trial. The authors acknowledge that main weaknesses in this study, 
namely its short duration and the small number of treatments in the sham-controlled phase: they state that a 
longer sham-controlled phase would have been necessary to demonstrate a difference between active and sham 
tDCS. They suggest that future studies utilise tDCS at higher intensities (>1mA), with daily treatment sessions, 
over longer periods, in more treatment-resistant patients. 
 
3.1.4 Palm (2011) 
33
 
This randomized double-blind placebo-controlled cross-over trial of tDCS in treatment resistant depression 
included 22 outpatients (14 women, 8 men: mean age 57 years): 20 with unipolar depression (17 with recurrent 
depression, and 3 with first-episode depression), and 2 patients with bipolar depression. All participants had 
failed to respond to at least two trials of antidepressants from different classes. Antidepressant medication was 
kept unchanged for at least 3 weeks before starting tDCS, and no medication changes were made during the 
study. Patients were randomized to two arms: [i] 10 sessions of active tDCS followed by 10 sessions of sham tDCS; 
[ii] 10 sessions of sham tDCS followed by 10 sessions of active tDCS. The anode was placed over left DLPFC (F3 on 
the 10-20 EEG international system), and cathode over right supraorbital region. The first 10 patients received 
stimulation sessions of 20 minutes at 1mA; the current setting was increased to 2mA for the subsequent 12 
patients. All patients received 20 tDCS treatments over 4 weeks. The sham stimulation included 15-second ramp-
up and ramp-down periods to simulate active tDCS sensations.  Electrodes were soaked in tap-water for the initial 
15 participants, but this was changed to normal saline solution, due to skin lesions at stimulation sites. The 
primary outcome measure was the HAMD-24 at 2 weeks and 4 weeks, secondary outcome measures included the 
BDI, CGI, PANAS and a series of cognitive tests.  Twenty patients completed the trial: no significant differences 
were found between active and sham tDCS on the primary outcome measure - although modeling the HAMD 
course via mixed model analysis showed that active tDCS was superior to sham tDCS in weeks 1 and 2 (p=0.0492). 
Subjective mood ratings showed a significant advantage for active over sham tDCS in positive emotions on the 
PANAS-pos and a trend for reduced negative emotions on the PANAS-neg. There were no significant between 
group differences in cognitive measures. Six of the 15 patients undergoing treatment involving use of tap-water 
soaked electrodes developed crusty skin lesions at the cathode site, but after normal saline solution was 
substituted, no further lesions were reported. Other adverse effects reported were minor, including slight 
headache and skin itchiness during treatment. Blinding integrity was not significantly different between groups.  
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Comment. The failure of active tDCS to separate from sham tDCS in this study may have been influenced by the 
small sample size, the change in treatment (from 1mA to 2mA) during the study, the cross-over design without an 
intervening no-treatment period, the higher degree of treatment resistance (average failed antidepressant trials 
2.9 vs. 1.0-2.6 in previous trials), the older age of patients (56 years, compared to 46-54 years in previous 
studies), and the use of concomitant antidepressant medication. 
 
3.1.5 Loo (2012) 
34
 
This randomised sham-controlled trial included 64 outpatients with DSM-IV defined major depressive episode 
(MDE) in the context of both unipolar and bipolar depression, with baseline MADRS score of 20 or more. Exclusion 
criteria included the presence of other Axis I mental disorders, excessive alcohol/drug use, neurological disorders, 
metal implants, history of heart or neurological disease, failure to respond to ECT in the index episode, pregnancy, 
and treatment with medications known to modulate tDCS effects (including benzodiazepines, anticonvulsants, 
dextromethorphan and pseudoephedrine). Subjects were either antidepressant medication-free for the duration of 
the trial, or continued on the antidepressants to which they had previously failed to respond (with no dose 
changes for at least 4 weeks before starting tDCS). Subjects were randomized to receive either active tDCS at 2mA 
for 20 minutes, with ramp-up and ramp-down for 30 seconds, or sham tDCS at 1mA for 30 seconds, with ramp-
up and ramp-down for 10 seconds. The anode was placed over left DLPFC (pF3 on the 10-20 EEG international 
system), the cathode lateral to the right orbit (F8 on the 10-20 EEG international system). Treatments were carried 
out five days per week for three weeks; each subject subsequently being offered another 15 sessions of open-
label active tDCS. Treatment responders (i.e. those whose MADRS scores reduced by at least 50% from baseline) 
were offered further weekly sessions of tDCS during the 1-month follow-up period. The primary outcome measure 
was the MADRS, assessed at baseline, after sessions 8, 15, 23 and 30, and at weeks 1 and 4 after trial completion. 
Other measures included the IDS, CGI-S, QIDS-C, QIDS-SR, CORE and a set of neuro-cognitive assessment tools. A 
significant interaction between group and time was seen on the primary outcome measure (MADRS scores), active 
tDCS being associated with lower MADRS scores during the sham-controlled phase (p=0.04; effect size 0.49), but 
there was no significant separation on other mood outcome measures. At 1-week follow-up, 16 out of 26 subjects 
in the active tDCS group met criteria for response (reduction in MADRS of at least 50% from baseline) compared to 
6 out of 26 in the sham tDCS group. The NNT for response at 3 weeks of active vs. Sham tDCS was 16.7; the NNT 
for response at 6 weeks of active tDCS vs. 3 weeks of sham tDCS was 2.6. There was one reported case of 
transient hypomania in the open phase of the trial (the patient had bipolar depression), other adverse effects were 
transient and mild to moderate in intensity, including skin redness, burning sensation, tingling and itchiness at 
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electrode sites, headache, dizziness and nausea. A blinding integrity test found no significant differences between 
groups. 
 
Comment. This trial included more participants and employed more robust treatment parameters (in terms of 
number of sessions, duration of blinded treatment, current settings, and follow-up period) than previous tDCS 
trials. Using the a priori primary outcome measure, this study confirmed that active tDCS has significantly greater 
antidepressant effects than sham tDCS over the 3-week sham-controlled phase. The magnitude of antidepressant 
effects (28% reduction in MADRS) was lower than in some previous studies 26,31 but patients in those trials were 
medication-free and the scope for tDCS-related improvement may have been greater in the absence of 
medication: a meta-analysis of treatment with rTMS with and without concomitant medication showed a similar 
finding35. The number of responders after six weeks of treatment was superior to the responder rate reported in 
the STAR*D trial (28.5%)4.The authors suggest that extending the treatment duration to 6 weeks may be associated 
with additional gains (though it is unclear whether the benefit is associated with a higher number of treatments, or 
with the extended duration of treatment). The study findings suggest a broadly equivalent effect size to that 
observed with antidepressant medication, despite selection of patients with a moderate degree of treatment 
resistance, many of whom were already taking antidepressant medication. The results suggest that more robust 
tDCS treatment parameters, in terms of current, number of sessions and overall duration of treatments, may be 
associated with better outcomes in depression. 
 
3.1.6 Blumberger (2012) 
36
 
 
This study explored the potential utility of tDCS in treatment-resistant depression. A total of 24 outpatients with a 
diagnosis of DSM-IV defined major depressive episode (MDE), a baseline HDRS score greater than 20, and fulfilling 
Stage II criteria (or above) on the Thase Scale for treatment resistance (i.e. failure to achieve remission or tolerate 
at least two trials of antidepressants from different classes) were recruited. Adjuvant medication (including 
antidepressants, antipsychotics and benzodiazepines) was permitted, providing dosage was stable for at least 4 
weeks before study treatment started and throughout the duration of the trial. Exclusion criteria included 
treatment with anticonvulsants, DSM-IV substance use disorder in the 6 months prior to potential trial 
commencement, an unstable co-morbid medical condition, a history of seizures, pregnancy, and DSM-IV 
borderline or antisocial personality disorder. Subjects were randomised to receive active (N=13) or sham (N=11) 
tDCS. Treating clinicians were aware of treatment allocation, but patients and outcome assessors were blind to 
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allocation. Fifteen treatment sessions were delivered on consecutive working days, over 3 weeks. The anode was 
placed over the left DLPFC (F3 according to the 10-20 EEG system), the cathode over the right DLPFC (F4 according 
to the 10-20 EEG system). Active treatment was delivered at 2mA for 20 minutes, the sham treatment included an 
initial 30 second period of stimulation at 2mA, and the current was then turned off. The primary outcome measure 
was change in HDRS from baseline to endpoint, secondary outcome measures including the proportion achieving 
symptom remission (HDRS<8) or response to treatment (50% reduction in severity). There was no significant 
difference between active and sham tDCS in the change in HDRS score (p=0.80): none of the subjects met HDRS 
remission criteria, and only 1 subject in each group met response criteria; and there were no significant between-
group differences in MADRS change or in BDI-II change. No serious adverse events were reported during the trial, 
though four subjects in each group reported skin tingling. Headache was reported by three subjects in the active 
group and by none of the sham group subjects: 1 participant in the sham group withdrew due to scalp irritation. 
The majority (73.7%) of subjects correctly guessed their treatment allocation at trial endpoint (60% in active group 
and 88.9% in the sham group). 
 
Comment. This sample had a higher degree of antidepressant treatment resistance when compared to participants 
in previous tDCS trials (the mean number of failed antidepressant trials was larger than 4, 46.2% of the active 
group and 18.2% of the sham group had a history of treatment with ECT; 23% of the active group and 9.1% of the 
sham group had failed a trial of ECT in the current episode of depression). This was the first study to focus on use 
of tDCS in treatment resistant unipolar depression in patients taking a wide variety of concomitant medication. The 
study limitations include small sample size, and probable under-powering (the power calculation required 48 
subjects, but only 24 were recruited): recruitment was stopped on ethical grounds after an interim analysis found 
no difference between treatment groups. The degree of treatment resistance in this cohort may have been too 
great to permit a detectable effect; and blinding may have been sub-optimal. Subjects who started antidepressants 
four weeks prior to the trial may have experienced antidepressant drug-related treatment effects during the trial. 
The active stimulation group was more treatment-resistant and more were taking benzodiazepines (which may 
impair the effects of neurostimulation). 
 
3.1.7 Brunoni (2013) 
27
 
This study explored the comparative safety and efficacy of tDCS, the antidepressant sertraline, and placebo, as 
well as their combinations in the treatment of Major Depressive Disorder. A total of 120 subjects with DSM-IV 
defined major depressive disorder (MDD), a baseline HDRS
17
 score greater than 17, and a low suicide risk, took 
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part in this double-blind randomized controlled trial. All subjects were free of antidepressant, antipsychotic and 
anticonvulsant medication for at least 5 half-lives of the drug, before onset of trial. Adjuvant benzodiazepines 
were permitted. Exclusion criteria included: other axis-I disorders (co-morbid anxiety disorders were permitted), 
substance use disorders, axis-II disorders, previous neurological conditions, severe axis-III disorders and specific 
contra-indications to tDCS (e.g. metallic implants in the head). Subjects who were prescribed sertraline in the 
current depressive episode were excluded. Subjects were randomized to one of four groups: Active tDCS + 
sertraline, tDCS + placebo medication, sham tDCS + sertraline, sham tDCS + placebo medication. Participants and 
assessors were blinded to treatment allocation; the treating clinicians were aware of allocation, but their 
interaction with participants was kept to a minimum. Medication and tDCS were initiated concurrently. tDCS was 
delivered using a bi-frontal montage, with the anode placed over the Left DLPFC (F3 according to the 10-20 EEG 
system), and the cathode over Right DLPFC (F4 according to the 10-20 EEG system). Twelve tDCS sessions were 
delivered – 10 sessions on consecutive week days (Monday to Friday) and two subsequent sessions at fortnightly 
intervals. Active tDCS was delivered using a current setting of 2mA, for 30 minutes per session; sham tDCS was 
delivered by switching the stimulator off after 1minute. Sertraline was administered at a fixed dose of 50mg per 
day. The primary outcome measure was change in MADRS score at 6 weeks; secondary outcomes were clinical 
response (defined as >50% reduction of the baseline MADRS score), clinical remission (defined as a MADRS score 
≤10), and scores on the HDRS17, Global Impression–Severity of Illness scale, and Beck Depression Inventory). At 
the main end point (6 weeks), there was a significant difference in MADRS scores when comparing the combined 
treatment group (sertraline/active tDCS) vs. sertraline + sham tDCS (mean difference, 8.5 points; 95% CI, 2.96 to 
14.03; p=.002), tDCS + placebo (mean difference, 5.9 points; 95% CI, 0.36 to 11.43; p=.03), and placebo/sham 
tDCS (mean difference, 11.5 points; 95% CI, 6.03 to 17.10; p_.001). Analysis of tDCS + placebo medication vs. 
sertraline + sham tDCS demonstrated comparable efficacies (mean difference, 2.6 points; 95% CI, _2.90 to 8.13; 
p=.35). Use of tDCS +placebo medication  (but not sertraline + sham tDCS) was superior to placebo + sham tDCS. 
Common adverse effects did not differ between interventions, except for skin redness on the scalp in active tDCS 
(p=.03).  
Active vs. sham tDCS was significantly superior for all outcomes (Odds Ratios for response and remission were, 
respectively, 1.63; 95% CI = 1.26–2.12 and 2.50; 95% CI = 1.26–2.49). There were 7 episodes of treatment-
emergent mania or hypomania, five of which occurred in the combined treatment group. 
Comment. 
This is largest trial to date of tDCS in depression; the factorial (2X2) design enables the authors to address issues 
of monotherapy vs. co-initiation of tDCS and antidepressant medication. The combination of sertraline and tDCS 
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(initiated simultaneously) was associated with better outcomes than in other arms of the trial, this may be a 
pointer to particular efficacy of co-initiated combination therapy. The choice of primary outcome endpoint at 6 
weeks differs from all previous tDCS RCTs in depression, as it encompasses both the 2 week intensive treatment 
phase, and 2 fortnightly add-on tDCS sessions. 
 
3.1.8 Bennabi (2014)
37
 
This study examined the utility of tDCS in treatment resistant depression. A total of 24 patients meeting diagnostic 
criteria for DSM-IV criteria for Major Depressive Disorder, with a baseline MADRS score greater than 24, and 
meeting stage II criteria (or above) for treatment resistance. All patients received a constant dose of escitalopram 
(10-20mg/d) over 4 weeks prior to tDCS treatment initiation. Concomitant treatment with benzodiazepine and/or 
second generation antipsychotics was allowed. Exclusion criteria included bipolar depression, psychotic features, 
neurological/ severe organic disease or treatment with First Generation Antipsychotics. Subjects were randomised 
to receive active (N=12) or sham (N=12) tDCS. Both subjects and clinicians were blinded to allocation. Ten 
treatment sessions were delivered over five consecutive days (two treatments per day). The anode was placed over 
the Left DLPFC, and the cathode over the Right supraorbital area. Active tDCS was delivered using 2mA intensity 
for 30 minutes per session. Sham tDCS was delivered using identical settings, but the current was gradually 
ramped down to zero mA.  Depression severity was assessed using the HDRS21 (primary outcome measure), 
MADRS, and BDI. Response was defined as a decrease of at least 50% from baseline HDRS score, remission was 
defined as a HDRS score of 8 or less. There was no significant difference between active and sham tDCS in the 
change in HDRS score (p=0.69): immediately after the course ended, in the active tDCS group there were 3 
subjects who responded and 2 who met criteria for remission. In the sham tDCS group there was 1 responder and 
no remitters. The authors comment that one subject developed mania and withdrew from the study, but they do 
not mention the group allocation for this subject. There were no other serious adverse events. The authors do not 
supply information about the degree of blinding integrity.  
 
Comment. This study is limited by the small number of subjects. There is considerable level of treatment 
resistance, and similarly to the Blumberger study36, subjects started a new antidepressant 4 weeks prior to the  
trial, and may have experienced medication-related effects.  
 
3.1.9 Segrave (2014)
28 
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This was the first study to examine the use of tDCS in conjunction with Cognitive Control Training (CCT), a type of 
neurocognitive training , which like tDCS is aimed at activating the DLPFC. The rationale for combining both 
modalities is that there is evidence to suggest that there are more pronounced functional outcomes when tDCS is 
applied to active brain regions, rather than to areas at rest.38-40. CCT is a novel therapeutic modality for depression, 
aimed at activation of the DLPFC through two targeted cognitive activities designed in reference to functional 
imaging data, to activate the DLPFC28: the first, a modified Wells Attentional Training (WAT) paradigm is a guided 
auditory process, directing attention through phases of focused attention, switching attention and divided 
attention; the second, is a modified Paced Serial Addition Task (PASAT), a mental arithmetic task. 27 subjects with 
DSM-IV Major Depressive Episode, whose baseline MADRS score was greater than 18 took part in this study. 
Exclusion criteria included: Lifetime history of neurological illness, mania, hypomania PTSD or psychosis, and 
substance use disorders in the year prior to study initiation. Subjects were either not prescribed antidepressant 
medication, or were stable on the same dose for at least 4 weeks prior to study initiation. Subjects were 
randomised to receive five sessions of either: 1.tDCS + CCT (N=9), or 2.sham tDCS + CCT (N=9), or 3. tDCS + 
sham CCT(N=9).  Participants and raters were blinded to allocation, but the operator was aware of allocation. 
Sessions were delivered on 5 consecutive working days. Active tDCS was delivered for 24 minutes per session 
using current setting of 2.0 mA. Sham tDCS was delivered using a 2minute fade out period. CCT started 2 minutes 
after initiation of tDCS session. The anode was placed over Left DLPFC (F3 according to the 10-20 EEG system), the 
cathode over the lateral aspect of the Right orbit (F8 according to the 10-20 EEG system). Results: there were no 
drop-outs during the course of treatment, tDCS was well tolerated and no serious adverse events were reported. 
There was a significant difference between the three arms in respect of the change in MADRS scores over time 
F
(4,48)
=4.63 (p=0.03). Post-hoc analysis demonstrates significant reduction in MADRS scores for subjects in the 
sham-tDCS+CCT group (p=0.02), and in the tDCS+sham-CCT group (p=0.04); there was a trend towards 
significance in the tDCS+CCT group (p=0.06). At 3-week follow-up, only the tDCS+CCT group showed significant 
difference from baseline MADRS scores (p<0.001). There were no significant differences in response rates 
immediately following the 5 treatment course (p=0.08). At 3 week follow up, there was a significant difference in 
response rates (p=0.04): tDCS+CCT 44%, sham tDCS+CCT 11%, tDCS+sham CCT 0%.  For the purpose of this 
meta-analysis, we included only 2 of the 3 study arms – comparing tDCS+CCT vs. sham tDCS+CCT. 
 
Comment. An interesting finding was the delayed onset of maximal therapeutic efficacy of the tDCS+CCT 
combination. This is not consistent with a previous study of the tDCS+CCT combination in healthy individuals41. 
This finding supports the inclusion of follow-up phases in future tDCS studies. 
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3.1.10 Brunoni (2014)
42
 
This is the second study examining the combination of tDCS and CCT for the treatment of depression. Subjects 
fulfilled criteria for DSM-IV major depressive episode, with a baseline HDRS score > 21; the age range was 18-65. 
Exclusion criteria included: 1. Bipolar disorder, substance use disorders, schizophrenia, personality disorders, and 
other co-morbid psychiatric disorders apart from anxiety disorders. 2. Neurological conditions. 3. Patient 
prescribed antipsychotics or tricyclic antidepressants. All subjects were taking antidepressant medication (SSRI or 
SNRI) with no dose changes for at least six weeks prior to Study initiation. Subject were randomised to 10 
treatments on consecutive working days, consisting of either: 1. CCT+sham tDCS (n=17) or 2. CCT+tDCS (N=20). 
The primary endpoint was 4 weeks post initiation (2 weeks of active treatment and 2 weeks of follow-up). tDCS 
parameters used were: 30 minutes per session at 2mA current setting, Anode over Left DLPFC (F3 according to the 
10-20 EEG system), Cathode over Right DLPFC (F4 according to the 10-20 EEG system). Sham tDCS used 30 sec 
ramp-in, 30 sec active stimulation and 15 sec ramp-out. The CCT intervention included only the modified PASAT, 
and was delivered during the final 15 minutes of each tDCS session. Results; tDCS was well-tolerated and no 
adverse effects were reported. There was 1 drop out from the active tDCS+CCT and 3 drop outs from the sham 
tDCS+CCT groups during the active treatment phase.  There were no statistically significant differences between 
the groups in respect of the primary outcome measure. Both groups demonstrated similar reductions of HDRS 
scores at week 2 (p=0.91) and at week 4 (p=0.71). There were no statistically significant differences in categorical 
response and remission rates at week 2 or at week 4. Older subjects demonstrated a stronger additional effect of 
tDCS when combined with CCT. There were no additional improvement in depressive symptoms during the 2-week 
follow-up period (in contrast to the findings in the  previous CCT+tDCS study28. 
Comment. This study demonstrated no statistically significant differences between active vs. sham tDCS, when 
added to a course of CCT in subjects with unipolar depression. The lack of significant difference at the end of the 
active treatment phase is consistent with the previous CCT+tDCS study28; however, in this study there was also no 
difference after a 2 week follow-up period.     
 
3.2 Published meta-analyses 
Our search of the literature identified 3 published meta-analyses of tDCS in depression. Their main design 
features and those of our own meta-analysis are summarised in table 2. 
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Meta 
analysis 
Date range Trials N subjects Power to 
detect “small” 
effect (g=0.30) 
Precision 
(pooled 
confidence 
interval width) 
Outcome measures Other 
analyses 
Kalu et al., 
2012 
01/01/1998-
05/2011 
6 Active tDCS: 
96 
Sham tDCS: 
80 
0.50 1.06 Continuous- mean 
change in depression 
rating scale scores 
Publication 
bias 
Berlim et 
al., 2013 
01/07/ 1998- 
20/08/2012 
6 Active tDCS: 
103 
Sham tDCS: 
97 
0.55  Categorical- reponse 
and remission rates 
Publication 
bias 
Shiozawa 
et al., 2014 
2006-
31/01/2014 
7 Active tDCS: 
167 
Sham tDCS: 
152 
0.76 0.66 Both categorical and 
continuous outcome 
measures 
Publication 
bias 
This meta-
analysis 
01/01/1995- 
30/04/2015 
10 (43% 
increase) 
Active tDCS: 
206 
Sham tDCS: 
187 (23% 
increase) 
0.84 (11% 
increase) 
0.52 (21% 
increase) 
Both categorical and 
continuous outcome 
measures 
Publication 
bias 
Power 
analyses 
Precision 
analyses 
 
 
Table 2:  Comparison of previously published and current meta-analyses of tDCS in depression 
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 1 
3.2.1 Kalu et al (2012) 
12
 2 
The first systematic review and meta-analysis of tDCS in the treatment of depression included randomized parallel 3 
or cross-over studies of active tDCS vs. sham tDCS controls, double blind allocation to treatment, and outcome 4 
measures including a clinician-rated depressive symptom severity scale (HDRS or MADRS), and an account of the 5 
change (%) in symptom severity. Six randomized controlled trials including a total of 96 patients in active tDCS 6 
arms and 80 patients in sham tDCS arms were included 26,29-31,33,34. Depressive symptom severity was reduced by a 7 
weighted mean of 28.9% (14.6-60%). A weighted mean of 21.8% (range: 0-80%) of RCT participants receiving 8 
active tDCS experienced categorical response (50% symptom severity reduction), and 6.1% (range 0-23%) 9 
experienced symptomatic remission (HDRS score < 8 or MADRS score <11). The wide variability between studies 10 
may have reflected differing levels of treatment resistance, concomitant medication use, and variability in delivery 11 
of tDCS between trials. The pooled estimate of effect size (Hedges' g) for depressive severity reduction between 12 
active and sham tDCS was 0.74 (Z=2.76, p=0.006, 95% confidence interval 0.21–1.27). All four studies which 13 
included 1-month follow-up data reported that the reduction in symptom severity with treatment was maintained 14 
(and in 2 studies increased in magnitude) at follow-up. No significant correlations were found with baseline 15 
symptom severity, concomitant antidepressant use, stimulation current strength or total number of sessions. The 16 
most common adverse effects in both active and sham tDCS study-arms were headaches, and local itchiness 17 
and/or redness at electrode sites. Skin-lesions were associated with the use of tap-water instead of saline solution 18 
for electrode preparation. Four cases of tDCS-associated hypomania were reported - 3 in published trials 30,34,43 and 19 
one in an ongoing trial 44. The authors conclude that tDCS is a potentially effective treatment for depression, but 20 
acknowledge limitations such as the small number of available studies, small number of participants, and 21 
heterogeneity in participant populations and treatment parameters. The authors called for large-scale studies with 22 
longer follow-up periods in more representative participant groups. 23 
 24 
3.2.2 Berlim et al (2013) meta analysis 
13
 25 
The second meta-analysis of tDCS in the treatment of MDD investigated the utility of tDCS using response and 26 
remission rates as outcome measures. Systematic review searched for publications which fulfilled the following 27 
inclusion criteria: randomised, sham-controlled, double-blind, parallel or cross-over design with at least 5 28 
subjects randomised to each study arm; participants aged 18-75, with a primary diagnosis of DSM-IV or ICD-10 29 
Major Depressive Episode (MDE) of a unipolar or bipolar nature; treated with at least 5 sessions of tDCS, at an 30 
intensity of at least 1mA, with the anode over the left DLPFC, tDCS being administered as either monotherapy or 31 
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augmentation strategy; publications in the English language. Exclusion criteria included enrolment of subjects with 32 
subsets of depression (e.g. post-partum or vascular depression); contemporaneous initiation of tDCS and another 33 
treatment for depression (e.g. antidepressant medication); and studies, which did not report response and/or 34 
remission rates. The literature search yielded 6 RCTs, including 5 of the 6 trials incorporated by Kalu et al. 12 in 35 
their meta-analysis 26,30,31,33,34: together with a more recent RCT 36. Overall, the dataset included 200 subjects with 36 
MDE, 103 of whom were randomised to active tDCS. Subjects received a 10.8 +/- 3.76 sessions of tDCS. The 37 
cohort had failed to respond to a mean of 2.36 +/- 1.19 trials of antidepressants. There was no significant 38 
difference in baseline depression severity between the active and sham tDCS groups (p=0.66). Using drop-out 39 
rates to assess overall treatment acceptability, there were no significant differences in drop-out rates between 40 
active (4.8%) and sham (5.1%) tDCS (p=0.86). There was no significant difference in blinding integrity between 41 
active and sham tDCS (p=0.41); 44.1% of active tDCS participants correctly guessed treatment allocation at study 42 
end, vs. 53.7% of sham tDCS participants. The overall rates of response and remission were not significantly 43 
different between the active and sham tDCS groups: response rates were 23.2% for active tDCS vs. 12.4% for sham 44 
tDCS, pooled OR = 1.97 (95% CI =0.85-4.56; p=0.11); and remission rates were 12.2% for active tDCS vs. 5.4% for 45 
sham tDCS, pooled OR = 2.13 (95% CI = 0.64-7.06; p=0.22). Active tDCS significantly out-performed sham tDCS 46 
when used as a monotherapy for MDE: OR =7.54 (95% CI = 1.630-34.8; p=0.01). There was no association 47 
between number of treatment sessions (5 vs. 10 treatments) or electrical current used (1 vs. 2 mA) and treatment 48 
efficacy. The authors highlighted limitations, including small sample sizes, little or no follow-up after treatment 49 
protocol is ended, and no differentiation between effects in unipolar and bipolar depression. 50 
 51 
3.2.3 Shiozawa et al (2014) 
14
 52 
This meta-analysis aimed to improve on previous meta-analyses by addressing two main areas: First, previous 53 
meta-analyses had utilised different methodologies for calculating effect size: the Kalu meta-analysis12 used 54 
continuous depression severity scores, whereas the Berlim meta-analysis13 used categorical response/remission 55 
rates. Second, previous meta-analyses had not includes data from the biggest tDCS for depression trial to date27. 56 
The inclusion criteria were: randomised, sham-controlled trials, providing data including continuous depression 57 
scores and categorical response + remission rates. The meta-analysis includes 7 RCTs 26,27,29,30,33,34,36, (N=259 58 
participants). Active tDCS significantly outperformed sham-tDCS on continuous depression scores (g=0.37; CI 59 
0.04-0.7). Odds Ratios for response and remission were respectively 1.63; 95% CI=1.26-2.12 and 2.50; 95% 60 
CI=1.26-2.49.  61 
 62 
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3.2.4 Discussion of previous meta-analyses 63 
The three published meta-analyses of tDCS for depression present inconsistent conclusions, possible due to a 64 
number of factors First, choice of outcome measures for calculating effect sizes - the 2012 meta-analysis 12 used 65 
percentage change in depressive rating scale scores from baseline to endpoint, whereas the 2013 meta-analysis 13 66 
used categorical response and/or remission rates, dichotomous outcomes which effectively raise the threshold for 67 
demonstrating differential effects between active and sham interventions. The 2014 meta-analysis 14 utilises both 68 
approaches: its conclusions are aligned with previous findings in respect of continuous depression rating scale 69 
data 12, but are at odds with previous conclusions regarding response/remission rates 13 - this may be due to the 70 
different studies included in this meta-analysis (in particular, the inclusion of the large 2013 trial 27). Second, the 71 
2013 meta-analysis includes a study which recruited participants with highly treatment-resistant depression 72 
(including those whose depression failed to respond to ECT, who were excluded from earlier trials). Third, there 73 
was an increased proportion of studies involving tDCS augmentation vs. Monotherapy in the 2013 meta-analysis: 74 
tDCS trials in which participants are allowed to continue antidepressant medication. This may limit the apparent 75 
effectiveness available to be demonstrated by tDCS, as the scope for active tDCS to increase the response and/or 76 
remission rates may be reduced when subjects are concurrently treated with antidepressant medication; some 77 
medications (for instance anticonvulsants) may actually reduce the efficacy of tDCS; and there may be an increased 78 
degree of treatment refractoriness in patients recruited to these trials. The 2014 meta-analysis 14 included  large 79 
RCT 27 in which ADM and tDCS were co-initiated – this group outperformed other arms of the trial (as well as 80 
giving rise to most manic switches), which may indicate a particular increase in antidepressant efficacy when tDCS 81 
& Sertraline are co-initiated.  82 
 83 
3.3 Narrative analysis of recent randomized controlled trials and meta-analyses of tDCS in depression 84 
The body of evidence examining the use of tDCS in depression has grown significantly in recent years, to include 85 
10 RCTs and 3 meta-analyses.  86 
As regards efficacy, RCTs have yielded mixed results: 4 RCTs29 show a statistically significant advantage for active 87 
tDCS over sham tDCS ('positive RCTs'), Whereas 6 RCTs28,33,36,37,42  failed to demonstrate a significant separation 88 
between active and sham treatments ('failed RCTs') (Table 3).  89 
 90 
Factors associated with these differential outcomes can be divided into participant-related factors and tDCS-91 
related factors (table 3) 92 
 93 
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Participant-related factors include treatment-resistance level, and concurrent treatment with medication or with 94 
CCT. Using the mean number of antidepressant medication trials before starting tDCS as a measure of the mean 95 
level of treatment resistance in each cohort, it seems that 4 RCTs28,33,36,37 recruited patients with higher levels of 96 
treatment resistance. The mean number of failed ADM trials in these studies was greater than 2  (compared to 97 
1.0-1.7 in all other RCTs for which data was available). All these studies found no advantage of active over sham 98 
tDCS, whereas 3: out of 4 RCTs in which tDCS was used for less treatment-resistant depression found evidence for 99 
superiority of active over sham tDCS26,27,34. The available data suggest that active tDCS is more likely to outperform 100 
sham tDCS in patients who have failed less than two trials of ADM, than in those who have failed more than two 101 
trials of ADM. It is notable that a similar pattern is seen in antidepressant drug RCTs: compared to patients who 102 
have not been treated or who have failed one ADM trial, patients who have not responded to more than 2 trials of 103 
ADM demonstrate a significantly lower response rate to subsequent ADM trials 45.  As regards concurrent 104 
medication usage, 2 out of 10 RCTs did not permit concurrent ADM use during the trial, both found significant 105 
superiority of active over sham tDCS26,29,42. The potential for additional improvement with tDCS in patients who are 106 
already prescribed an antidepressant or undergoing CCT may be limited, in comparison with patients who are 107 
receiving tDCS monotherapy. Antidepressants may also directly interfere with tDCS efficacy. 108 
 109 
TDCS-related factors include current settings, number of tDCS sessions and session duration, as well as electrode 110 
placement. Of the 4 positive RCTs, three used the higher (2mA) rather than the lower (1mA) current setting. By 111 
contrast, of the six failed RCTs, two used the lower current setting (1mA) in all participants 30, or in some of them 112 
33. Palm et al.33 compared the outcomes for participants who received tDCS at 1mA vs. 2mA and found there was no 113 
significant difference (p=0.38) between groups: however, this trial recruited participants with treatment resistant 114 
depression, in whom the difference in efficacy between current levels may not have been sufficiently great to be 115 
associated with significantly different treatment outcomes. As regards the number of sessions, the number of 116 
sessions used in RCTs ranges from 5 to 15. Of the four positive RCTs, one involved 5 treatment sessions, two 117 
involved 10 treatment sessions, and a single trial involved 15 sessions. The negative RCTs include 2 trials 118 
involving 5 sessions, three involving10  sessions, and one involving 15 sessions. 119 
 120 
Of course, it may be that these factors influence the efficacy of tDCS in an additive fashion: among the 6 failed 121 
RCTs, 4 trials recruited participants with higher levels of treatment-resistance. The only failed RCT which reported 122 
recruiting participants with lower levels of treatment-resistance mean number of failed ADM courses <2) 30, 123 
combined a short course of tDCS (5 treatment sessions), with a low current setting (1mA). 124 
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Name Diagnosi
s N 
active, 
sham 
Age 
(S.D.) 
Gender 
% 
Female 
Rating 
Scale 
tDCS 
Curren
t (mA) 
tDCS 
Session 
Duration 
(min) 
tDCS 
Montage: 
anode, 
cathoode 
Number of 
tDCS 
Sessions 
Treatment 
resistance 
level 
Con-
current 
ADM 
Con-
current 
CCT 
Depression 
outcome  
Fregni 200629 Unipolar  9,9 48.2 (10) No data MADRS 1.0 20 F3 , FP2 5 no data No No Active>Sham 
Boggio 200826 
Unipolar  21,10 49 (7.4) 67.5% HDRS 2.0 20 F3 , FP2 10 1.7 No No Active>Sham 
Loo 201030 
Unipolar  20,20 47.3 
(11.3) 
55% MADRS 1.0 20 F3 , FP2 5 Active 1.0 
Sham 1.7 
Yes No Active=Sham 
Palm 201133 
Unipolar 
& bipolar  
11,11 57 (12) 50% HDRS 1.0 or 
2.0 
20 F3 , FP2 10 Active 2.9 
Sham 2.91 
Yes No Active=Sham 
Loo 201234 
Unipolar 
& bipolar  
33,31 48.2 
(12.5) 
46.6% MADRS 2.0 20 F3, F8 15 Active 1.71 
Sham 1.79 
Yes No Active>Sham 
Blumberger 
201236 
Unipolar  13,11 42.7 
(11.6) 
45.6% HDRS 2.0 20 F3, F4 15 Active 4.3 
Sham 4.1 
Yes No Active=Sham 
Brunoni 201327 Unipolar  30,30 42 (12) 68% MADRS 2.0 30 F3, F4 10+2 1.7 Yes No Active>Sham 
Bennabi201437 Unipolar  12,12 61.8 
(16.3) 
75% HDRS 2.0 30 F3 , FP2 10 (5 days 
twice daily) 
100% > 2 Yes No Active=Sham 
Segrave 201428 
Unipolar  9,9 40.4 
(14.5) 
37% MADRS 2.0 24 F3, F8 5 3.0 Yes Yes Active=Sham 
Brunoni 201442 
Unipolar  20,17 18-65 70.2% HDRS 2.0 30 F3, F4 10 35-41% > 2 Yes Yes Active=Sham 
Table 3: Participant-related factors, tDCS-related factors and tDCS trial depression outcomes: RCTs of tDCS in depression listed in chronological 126 
order. Depression outcome is a categorical statement as to whether active tDCS out-preformed sham tDCS in terms of depression outcome 127 
measures (p≤0.05), at the end of active treatment course. ADM = Antidepressant Medication. CCT=Cognitive Control Training. The degree of 128 
treatment resistance is indicated by the number of ADM trials failed prior to starting tDCS.129 
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 130 
3.4 Analysis of published meta-analysis efficacy factors 131 
Consideration of the 3 published meta-analyses, provides the following efficacy-related insights: 132 
3.4.1 Kalu et al. 2012 12. This meta analysis utilised continuous outcome measures and showed that active tDCS 133 
was associated with significant reduction in symptom severity compared with sham tDCS. It found that meta-134 
regression with participant related factors (baseline severity, concurrent treatment with antidepressant 135 
medication), and with tDCS-related factors (number of sessions, current settings) did not yield any significant 136 
correlations. 137 
 138 
3.4.2 Berlim et al. 2013 13. This meta-analysis utilised categorical response and remission outcome measures, and 139 
concluded that there was insufficient evidence to support tDCS as superior to placebo in achieving response or 140 
remission from depression. Neither participant-related, nor treatment-related factors were significantly correlated 141 
with differential treatment outcomes. 142 
 143 
3.4.3 Shiozawa et al. 201414. This meta-analysis utilised both continuous and categorical outcome measures, and 144 
found that tDCS with statistically superior to sham tDCS in the treatment of depression In both outcome domains. 145 
Meta-regression of both categorical and continuous outcome measures did not yield any statistically significant 146 
correlation between participant-related or treatment-related factors and treatment outcomes. 147 
 148 
1.5 Published meta-analysis safety and tolerability findings: 149 
The three published meta-analyses contribute the following insights into safety and tolerability:  150 
 151 
1. Kalu et al. 2012 12. The most common adverse effects reported by studies included in the systematic review 152 
were of a minor nature including headaches, itchiness and redness of skin underlying the electrodes.  Skin lesions 153 
reported by Palm et al. 201146 were not observed once the electrodes were soaked in saline solution rather than 154 
tap water.  The authors note that although adverse effects were more commonly reported in the active tDCS than 155 
in sham tDCS groups, the differences were not statistically significant.  There were several reports of „treatment 156 
emergent‟ hypomanic episodes. 157 
 158 
2. Berlim et al. 2013 13. Dropout rates at study end did not demonstrate a statistically significant difference 159 
between active and sham tDCS groups.  The authors did not comment on safety aspects. 160 
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 161 
3. Shiozawa et al. 201414. No statistically significant differences were found between acceptability (as measured by 162 
dropout rates) of active versus sham tDCS. 163 
 164 
 165 
4. CURRENT META-ANALYSIS: Continuous Treatment effects 166 
Across all studies the combined treatment effect was significant and consistent with a small effect size (k=11, 167 
g=0.30, 95% CI=[0.04, 0.57], p= .027)(see Figure 2a). The „probability of superiority‟ metric 30 indicated a 62% 168 
chance that a randomly sampled individual receiving active tDCS would have a greater reduction in depressive 169 
symptoms than a randomly sampled individual receiving sham tDCS 95% CI [52%  72%].  A „leave one out‟ analysis 170 
revealed that removing Boggio et al (2008) 26, Loo et al (2012)34, or the concurrent Sertraline group of Brunoni et al 171 
(2013)27 would reduce the effect to non-significance (largest p =.078, smallest g = 0.23). The meta-analytic 172 
combination of effects yielded a valuable increase in precision. From the earliest study to the most recent, the 173 
margin of error (width of one arm of the confidence interval: MOE) decreased from 1.18 to 0.26. The test for 174 
heterogeneity was significant (Q(10) =19.27, p= .037) and the I
2
 statistic indicated that 40% of the heterogeneity 175 
between studies could not be accounted for by sampling variability, justifying the use of a random effects model. 176 
 177 
4.1 Fail-safe N analyses 178 
The "fail safe N" calculation using the Rosenthal approach 22, revealed that 27 unpublished studies averaging null 179 
results would be required in order for the treatment effect to dip below significance (a=.05). Additionally, we used 180 
the Orwin fail-safe N calculations 21 to estimate the number of unpublished studies averaging null results that 181 
would be required to reduce the effect size to a range of target levels, this data is plotted in Figure 2b.  182 
 183 
4.2 Publication bias 184 
A funnel plot of the outcomes is shown in Figure 2c. To examine the sensitivity of the data to publication bias we 185 
employed the nonparametric "trim and fill" method 47. The procedure estimated that one study (on the left of the 186 
summary effect) could have been suppressed due to publication bias. Imputing this missing study and repeating 187 
the analyses marginally reduced the effect size (k=12, g=0.22, 95% CI=[-0.11, 0.56], p = .195). 188 
 189 
4.3 Precision and power analyses 190 
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By using our interval of effect size estimates (g=0.30, 95% CI [0.04 0.57]) as a plausible population estimate of the 191 
treatment effect, we estimated the sample size required for future trials to yield target levels of precision, 192 
expressed in terms of the maximum confidence interval width for g. All analyses were performed to provide a level 193 
of 99% assurance that the confidence interval would be sufficiently narrow. This data is plotted in Figure 2d. 194 
 195 
For sample size planning, we estimated that for an individual study to detect the summary effect estimated by our 196 
meta analysis at the p =.05 level with 80% power, an N of at least 346 (173 in each group, assuming equal 197 
allocation) would be required in both the treatment and control group (with the total N required to detect the 198 
upper and lower bound being 49 and 12693 respectively) . These estimates by far exceed the mean sample size of 199 
the studies included in the meta analysis (N=36). These analyses suggest that the studies included in the analysis 200 
do not meet the criterion for adequate statistical power. 201 
 202 
4.4 Moderator analysis for continuous outcomes 203 
A summary of the one-moderator models is shown in table 4. Treatment resistance level was removed due to the 204 
inconsistent reporting (for separate groups, or for all participants combined, or no exact values) which prevented a 205 
useful and informative component of this analysis. Meta regression did not detect any significant moderators of 206 
the treatment effect – no one-moderator model provided a better fit to the data than an empty (no moderator 207 
model). In a multiple regression model, we calculated the proportional contribution of each moderator to the 208 
overall R2, collapsed across orderings of regressors. This revealed that concurrent Antidepressant Medication 209 
(ADMs) and concurrent Cognitive Control Training (CCT) were the most important predictors, both impacted 210 
negatively on the  treatment effect and accounted for 47% and 36% of the total variation explained respectively 211 
(Figure 2e). Closer examination of these factors revealed that samples who were not taking concurrent ADMs 212 
(g=0.71,95% CI[0.12 1.29], p=.019) had a larger treatment effect than those who were (g=0.18,95% CI[-0.16 213 
0.51], p=.302). Similarly, samples that did not receive concurrent CCT (g=0.39,95% CI[0.13 0.65], p=.004) had a 214 
larger treatment effect than those who did (g=-0.20,95% CI[-0.82 0.41], p=.517).  No interactions between 215 
moderators could be tested, due to empty cells in the model matrices.   216 
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 217 
Moderator k df Qo p R2 
b
0
 
b
1
 
Current 11 1 0.50 .481 0.0 0.57 -0.30 
Number of 
sessions 
11 1 0.00 .964 0.0 0.28 0.00 
Session 
length 
11 1 014 .705 0.0 0.35 -0.11 
Total tDCS 
time 
11 1 0.07 .791 0.0 0.43 -0.00 
Total current 11 1 0.41 .783 0.0 0.41 -0.00 
ISI 11 1 0.50- .481 0.0 0.26 0.30 
Diagnosis 11 1 0.00 .995 0.0 0.31 -0.00 
Concurrent 
ADMs 
11 1 2.35 .125 0.0 0.70 -0.53 
Concurrent 
CCT 
11 1 3.03 .082 41.2 0.39 -0.59 
 218 
Table 4: A summary of the calculated one-moderator models and associated significance levels. Q
0
 is the Wald-219 
type chi squared value for the omnibus test of model coefficients. R2 is the pseudo R2. b
0
 and b
1
 are the slope and 220 
intercept respectively. (ISI=inter-session interval in days, ADM = Antidepressant Medication)   221 
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 222 
5 CURRENT META-ANALYSIS: Categorical treatment effects (Response and Remission rates) 223 
 224 
Data for response rates were available from 9 of the 11 effects (Figure 3a). The pooled LOR for response was 225 
positive, but did not reach significance (k= 9, LOR = 0.36, 95% CI[-0.16, 0.88], p = .176), Heterogeneity between 226 
studies did not exceed that expected by chance (Q (8) = 6.18, p= .627) and the I2 statistic indicated that only 227 
0.86% of the heterogeneity could not be explained by sampling error. Cumulative meta-analysis revealed that the 228 
meta-analytic combination of effects yielded an increase of precision from an MOE of 1.71  to 0.52. Data for 229 
remission rates were available from 9 of the 11 effects (Figure 3b). Consistent with response rates, the pooled LOR 230 
for remission was positive, but did not reach significance (k= 9, LOR = 0.25, 95% CI [-0.42, 0.91], p = .468), 231 
Heterogeneity between studies did not exceed that expected by chance (Q(8)=4.68, p= 791) and the I2 statistic 232 
indicated that all heterogeneity could be attributed to sampling error. Cumulative meta-analysis revealed that the 233 
meta-analytic combination of effects yielded an increase of precision from an MOE of 2.97 to 0.66. 234 
 235 
5.1 Fail safe N analyses 236 
Owing to the non-significant summary effects for response and remission, we did not compute fail-safe N 237 
analyses based on a nominal significance level. Instead, we used the Orwin method to assess the impact of 238 
publication bias on effect size. These data are plotted in Figure 3c.   239 
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 240 
5.2 Publication bias 241 
Analyses revealed that no studies were trimmed and filled on the opposite side of zero in either the response or 242 
remission meta-analyses. Furthermore, both funnel plots were broadly symmetrical, suggesting a low risk of 243 
publication bias (figure 3d & 3e).  244 
 245 
5.3 Moderator analysis for categorical outcomes 246 
Meta regression revealed no statistically significant moderators of either response or remission rates. 247 
 248 
6 CURRENT META-ANALYSIS: SAFETY AND TOLERABILITY:  249 
 250 
Dropout rates were available from 9 studies (table 5) and were analysed in a random effects model using 251 
the log odds ratio as an effect size measure (effect sizes greater than 0 indicate a greater likelihood of dropout in 252 
the active relative to the sham tDCS group). The analysis revealed no significant differences in drop out rates (k= 9 253 
LOR = 0.05, 95% CI= [-1.0, 1.10], p = .928).  254 
  255 
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Study N-
active 
drop out rate due to 
adverse effects - 
active tDCS 
N-
control 
drop out rate due to 
adverse effects -  sham 
tDCS 
p 
Fregni 200629 9 0 9 0 1 
Boggio 200826 21 0 19 0 1 
Loo 201030 20 0 20 0 1 
Palm 201133 11 0 11 0 1 
Loo 201234 33 1 31 1 .964 
Blumberger 201236 13 1 11 0 .558 
Brunoni 201327 
 
60 3 60 1 .347 
Brunoni 201442 
 20 1  17  3  .245 
Segrave 201428 
9 0 9 0 1 
 256 
 257 
Table 5 : Drop out rates due to adverse events in blind phase of tDCS depression RCTs 258 
  259 
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 260 
7. DISCUSSION 261 
 262 
We carried out a meta analysis of 10 RCTs comparing active tDCS to sham tDCS, including 393 participants with 263 
major depressive episodes in the context of unipolar or bipolar disorders. tDCS was used as mono therapy or as 264 
adjunctive treatment for depression in conjunction with medication and/or Cognitive Control Training (CCT). 265 
Analysis of continuous outcomes - depression rating scale scores, demonstrates clear superiority of active tDCS 266 
over sham tDCS in the treatment of MDE. The combined treatment effect was significant and consistent with a 267 
small effect size (k=11, g=0.30, 95% CI=[0.04, 0.57], p= .027) (Figure 2). 268 
It is important to highlight the findings from our precision and power analyses: These indicate that for an 269 
individual study to detect the summary effect (g=0.30) at the p =.05 level at 80% power, a total (combined 270 
treatment and control) N of at least 346 would be required. The mean total sample size of the studies included in 271 
the meta analysis is 36 - it is therefore likely that the RCTs included lacked sufficient statistical power. Given that 272 
an N of 346 is of considerable size, future studies may wish to focus on enhancing the precision of their interval 273 
based estimates within practical and financial constraints, rather than placing too much stock in conclusions based 274 
on null hypothesis significance testing. In this context, a priori power and precision analyses (and explicit 275 
reporting of the associated values) are recommended to enhance interpretation of data relating to tDCS efficacy in 276 
future RCTs. It is, of course, worth noting that power is not simply a function of sample size. Correspondingly, 277 
enhancements in the design of RCTs, including rigorous eligibility criteria and optimizing a sensitive study design 278 
and endpoint may decrease the number of participants required to detect an effect. The issues surrounding power, 279 
in turn, also go some way towards providing a possible explanation for the lack of statistically significant 280 
differences between active and sham tDCS in the categorical response and remission analyses that we carried out. 281 
Categorical outcome measures are more robust and clinically meaningful, but require a larger sample size to 282 
demonstrate an effect. We found that both response and remission rates showed a positive pooled LOR but failed 283 
to reach statistical significance at the p=.05 level. These findings are consistent with the findings from earlier 284 
meta-analyses: Kalu et al. (2012)12 used continuous outcome measures and found a significant superiority of 285 
active over sham tDCS; whereas Berlim et al. (2013) 13, used categorical outcome measures and failed to 286 
demonstrate significant differences. The more recent meta analysis Shiozawa et al (2014)14 used both types of 287 
outcome measures and demonstrated significant superiority of active over sham tDCS in both continuous and 288 
categorical outcome measures. This difference in findings is likely to be mainly due to the way we analyzed data 289 
from the largest tDCS trial to date 27 – we decided to analyze the outcomes at week 2, immediately following the 290 
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daily tDCS treatment phase – in contrast to analyzing the outcomes at 6 weeks (the primary outcome measure for 291 
the trial), following 2 fortnightly “top-up” sessions. The rationale for our choice being that most other RCTs we 292 
included in the meta-analysis used an endpoint at the termination of the intensive tDCS treatment phase. The 293 
outcomes at week 6 demonstrate an added degree of separation between active and sham tDCS. Repeating our 294 
analyses with week 6 as an endpoint revealed that this is sufficient to provide overall statistical significance to the 295 
categorical analysis (response: LOR = 0.81, [0.28, 1.34], p= .003, remission: LOR = 0.73, [0.13 1.33], p =.017)  296 
and slightly increase the magnitude of the continuous effect. (g=0.37, [0.09, 0.65], p= .008)   This accords with 297 
the findings from other tDCS trials28,34,48, indicating that at follow up, participants‟ depression rating scales score 298 
continued to improve. We also decided to separately analyze the data from participants who received sertraline 299 
and those who received placebo medication in the Brunoni et al. 2013 trial27 – this created two separate effects 300 
(hence although we included 10 RCTs, we analyzed k=11 effects). Moderator analysis demonstrated that although 301 
no moderators reached statistical significance at the level of p=.05, concurrent use of antidepressant medication, 302 
and concurrent use of Cognitive Control Training were the most important predictors, accounting for 47% and 36% 303 
of the total variation explained respectively (Figure 2e). Notably, these moderators remained the most important 304 
when outcomes for the Brunoni et al. 2013 trial27 trial were analyzed at week 6, with the concurrent ADMs factor 305 
reaching significance (R2= 24.15, Q(1)=4.94, p=.026). 306 
Our moderator analyses revealed that samples who were not taking concurrent ADMs (g=0.71,95% CI[0.12 1.29], 307 
p=.019) had a larger treatment effect than those who were (g=0.18,95% CI[-0.16 0.51], p=.302). Similarly, 308 
samples that did not receive concurrent CCT (g=0.39,95% CI[0.13 0.65], p=.004) had a larger treatment effect 309 
than those who did (g=-0.20,95% CI[-0.82 0.41], p=.517).  It is of note, that the largest trial to date 27 included a 310 
group of participants, in whom tDCS and pharmacological antidepressant therapy were concurrently initiated – the 311 
authors report that this group did particularly well in terms of  depression outcomes, and go on to postulate that 312 
simultaneous initiation of tDCS and ADM may confer added benefits in patients with MDE. One should note that 313 
these participants were treated with a low dose of antidepressant medication (sertraline 50mg daily). Insufficient 314 
data prevented us from conclusively analyzing the effect of treatment-resistance level as a moderator of tDCS 315 
outcomes. More trials are needed in order to improve the precision of moderator analyses; this is currently limited 316 
due to small k. The evidence suggests tDCS has a good safety and acceptability profile, with only mild adverse 317 
effects reported in most trials. There were no statistically significant differences in the drop-out rates between 318 
active and sham tDCS groups in any of the RCTs. The only serious adverse event recorded in published tDCS RCTs 319 
was a case of suicide, which was considered by the authors as unlikely to be directly related to tDCS 30. Early 320 
reports of tDCS trials included descriptions of burns to the skin underlying scalp electrodes, but this has not been 321 
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reported since researchers started using physiological saline rather than water to soak electrodes prior to use 49. 322 
Several cases of tDCS-associated hypomanic episodes have been reported in the literature 12,14,27.  323 
This meta-analysis offers several improvements compared to previous publications (Table 2): The literature search 324 
extends up to April 2015, and therefore captures 3 new RCTs (43% increase), which were not included in previous 325 
meta-analyses. This enabled us to increase the number of subjects by 23%. We were able to assess the effect of 326 
adding tDCS to CCT; this was not previously meta-analytically addressed. The power to detect “small” effects is 327 
increased, as is the precision (21% improvement in pooled confidence interval width). We also performed power 328 
and precision analyses to directly inform future research in terms of sample size planning. 329 
Limitations:  The main limitation of this meta analysis is the low number of participants in most trials included. As 330 
demonstrated by our precision and power calculations, all but one of these trials 27 are probably underpowered. 331 
This is likely to explain the lack of separation between active and sham tDCS in terms of categorical response and 332 
remission outcomes; as well as limiting the number of moderators reaching statistical significance. There is a lack 333 
of evidence regarding longer-term outcomes of tDCS in the acute and maintenance treatment of depression.  334 
 335 
8. Conclusions:  336 
 337 
Based on current evidence, the following conclusions may be drawn: First, tDCS may represent an effective 338 
treatment option for patients presenting with major depressive episodes. Second, tDCS offers a generally 339 
acceptable tolerability profile, which may make it a useful alternative to antidepressant medication in patients who 340 
do not wish to take medication and for those who cannot tolerate antidepressant medication. Third, the current 341 
body of evidence does not support the use of tDCS in treatment resistant depression. Fourth, the current body of 342 
evidence does not support the use of tDCS as an add-on augmentation treatment for depressed patient who are 343 
already taking an antidepressant or undergoing Cognitive Control Training (CCT). However, there may be an 344 
advantage for concurrently initiating treatment with an antidepressant and tDCS. Further research is needed, in 345 
particular, involving larger sample sizes over longer periods of treatment.346 
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 349 
Figure 1 Study selection and quality assurance: (a) PRISMA1 study-selection flowchart for our systematic review and meta-analysis. RCT = 350 
Randomised Controlled Trial. (b) Summary of risk of bias in line with the Cochrane Collaboration‟s tool for assessing risk 351 
of bias in randomised trials25. Green circles represent low risk; yellow circles represent unclear risk of bias. The summary 352 
was generated using Cochrane‟s Review Manager software (RevMan5.3) -http://tech.cochrane.org/revm353 
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Figure 2. (a) Forest plot of effect sizes for active versus sham treatment. Error bars are 95% confidence intervals. 355 
Dotted red line depicts pooled effect. Shaded red region is 95% confidence interval. (b) Orwin fail-safe N analyses 356 
(c) Funnel plot. Dotted line is the pooled effect size, colored lines are p values (e.g. red=.05, yellow = .01, blue= 357 
.001). (d) Outcome of precision analyses. For instance, to have 99% assurance that a 95% CI will be less than 0.8, 358 
approximately 50 participants per group would be required.  (e) Relative importance of each moderator. Note that 359 
total TDCS time, amplitude, session length and number of sessions were removed due to multi-colinearity. Total 360 
current is instead included to summarize these variables. 361 
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Figure 3. (a) Forest plot of effect sizes for active versus sham treatment: response rates. (b) Forest plot of effect 363 
sizes for active versus sham treatment: remission rates.  Error bars are 95% confidence intervals. Dotted red line 364 
depicts pooled effect. Shaded red region is 95% confidence interval. (c) Orwin fail-safe N analyses (d) Funnel plot: 365 
response rates. (d) Funnel plot: remission rates. Dotted line is the pooled effect size, colored lines are p values 366 
(e.g. red=.05, yellow = .01, blue= .001). 367 
 368 
369 
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Potential moderator Units Descriptive Statistics 
Current  mA (Boolean) k = 11 
1mA (k = 2) 
2mA (k = 9) 
Course delivered Number of sessions  k= 11 
M= 9.55 
SD = 3.50 
Range = 5-15 
Session duration Minutes per session (Boolean) k = 11 
20 mins (k=7) 
30 mins (k=4) 
Total tDCS time Number of sessions x session 
duration (minutes) 
k= 11 
M =229.09 
SD = 87.80 
Range = 100- 300 
Total current delivered mA x number of sessions x session 
duration 
k = 11 
M = 430.91 
SD = 210.97 
Range = 100- 600 
Inter-session intervals Days (Boolean) k = 11 
1 day (k=9) 
2 days (k=2) 
Diagnosis  k=11 
unipolar (k=9) 
unipolar and bipolar (k=2) 
Concurrent anti-depressant 
medications (ADMs) 
 k=11 
Concurrent ADMs (k=8) 
No-concurrent ADMs (k=3) 
Concurrent cognitive control 
therapy (CCT) 
 k=11 
Concurrent CCT (k=2) 
No concurrent CCT (k=9) 
   
Treatment resistance level Number of previous courses of 
antidepressants failed in current 
episode 
k= 9 (see table 3) 
 
   
   
1 
2 
3 
4 
5 
Tables 1-5
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6 
Meta 
analysis 
Date range Trials N subjects Power to 
detect “small” 
effect (g=0.30) 
Precision 
(pooled 
confidence 
interval width) 
Outcome measures Other 
analyses 
Kalu et al., 
2012 
01/01/1998-
05/2011 
6 Active tDCS: 
96 
Sham tDCS: 
80 
0.50 1.06 Continuous- mean 
change in depression 
rating scale scores 
Publication 
bias 
Berlim et 
al., 2013 
01/07/ 1998- 
20/08/2012 
6 Active tDCS: 
103 
Sham tDCS: 
97 
0.55  Categorical- reponse 
and remission rates 
Publication 
bias 
Shiozawa 
et al., 2014 
2006-
31/01/2014 
7 Active tDCS: 
167 
Sham tDCS: 
152 
0.76 0.66 Both categorical and 
continuous outcome 
measures 
Publication 
bias 
This meta-
analysis 
01/01/1995- 
30/04/2015 
10 (43% 
increase) 
Active tDCS: 
206 
Sham tDCS: 
187 (23% 
increase) 
0.84 (11% 
increase) 
0.52 (21% 
increase) 
Both categorical and 
continuous outcome 
measures 
Publication 
bias 
Power 
analyses 
Precision 
analyses 
7 
8 
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pt9 Name Diagnosi
s N 
active, 
sham 
Age 
(S.D.) 
Gender 
% 
Female 
Rating 
Scale 
tDCS 
Curren
t (mA) 
tDCS 
Session 
Duration 
(min) 
tDCS 
Montage: 
anode, 
cathoode 
Number of 
tDCS 
Sessions 
Treatment 
resistance 
level 
Con-
current 
ADM 
Con-
current 
CCT 
Depression 
outcome  
Fregni 200629 Unipolar  9,9 48.2 (10) No data MADRS 1.0 20 F3 , FP2 5 no data No No Active>Sham 
Boggio 200826 
Unipolar  21,10 49 (7.4) 67.5% HDRS 2.0 20 F3 , FP2 10 1.7 No No Active>Sham 
Loo 201030 
Unipolar  20,20 47.3 
(11.3) 
55% MADRS 1.0 20 F3 , FP2 5 Active 1.0 
Sham 1.7 
Yes No Active=Sham 
Palm 201133 
unipolar 
& bipolar  
11,11 57 (12) 50% HDRS 1.0 or 
2.0 
20 F3 , FP2 10 Active 2.9 
Sham 2.91 
Yes No Active=Sham 
Loo 201234 
unipolar 
& bipolar  
33,31 48.2 
(12.5) 
46.6% MADRS 2.0 20 F3, F8 15 Active 1.71 
Sham 1.79 
Yes No Active>Sham 
Blumberger 
201236 
Unipolar  13,11 42.7 
(11.6) 
45.6% HDRS 2.0 20 F3, F4 15 Active 4.3 
Sham 4.1 
Yes No Active=Sham 
Brunoni 201327 Unipolar  30,30 42 (12) 68% MADRS 2.0 30 F3, F4 10+2 1.7 Yes No Active>Sham 
Bennabi201437 Unipolar  12,12 61.8 
(16.3) 
75% HDRS 2.0 30 F3 , FP2 10 (5 days 
twice daily) 
100% > 2 Yes No Active=Sham 
Segrave 201428 
Unipolar  9,9 40.4 
(14.5) 
37% MADRS 2.0 24 F3, F8 5 3.0 Yes Yes Active=Sham 
Brunoni 201442 
Unipolar  20,17 18-65 70.2% HDRS 2.0 30 F3, F4 10 35-41% > 2 Yes Yes Active=Sham 
10 
11 
12 
13 
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